You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Scancell’s July 23, 2026 merger agreement with Neuphoria provides approximately 3.77246 Scancell ADSs and one contingent value right per Neuphoria share; closing requires at least $75,000,000 in concurrent financing proceeds.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCNLD
this stock
Scancell Holdings plc
|
$156.02M | — | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Scancell’s July 23, 2026 merger agreement with Neuphoria provides approximately 3.77246 Scancell ADSs and one contingent value right per Neuphoria share; closing requires at least $75,000,000 in concurrent financing proceeds.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCNLD | -16.9% | -39.9% | -69.7% | -2.5% | -20.1% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | -16.2% | -38.5% | -72.2% | -4.0% | -32.6% |
